Paolo Ghia, Andrzej Pluta, Malgorzata Wach, Daniel Lysak, et al.
Conclusion: Acalabrutinib monotherapy significantly improved PFS with a more tolerable safety profile compared with IdR/BR in pts with R/R CLL.
Suzanne Verlhac, Catherine Paillard, Charlotte Jubert, Marie Petras, et al.
Conclusion: This prospective trial comparing the outcome of stenosis in stroke-free SCA-patients with history of abnormal-TCD shows a significantly better outcome after SCT than on chronic transfusion encouraging to early systematically recommend SCT in those with stenosis and a MSD.
Hitoshi Takizawa, Yoshikazu Hayashi, Maiko Sezaki, Sumit Sheoran, et al.
Cécile Lopez, Esteve Noguera, Vaya Stavropoulou, Zakia Aid, et al.
Conclusion: By integrated analysis of patient samples and transgenic mouse models, we showed that aggressiveness and phenotypes in pediatric AML result from ontogeny-related differential susceptibility to transformation by several fusion oncogenes, which also provides a basis for the higher prevalence of AMKL in pediatric patients. These data also nourish the perspective that direct targeting of the fusion would alter leukemia maintenance and restore a multilineage differentiation potential.
Petra Langerbeins, Jasmin Bahlo, Christina Rhein, Henrik Gerwin, et al.
Conclusion: The results of this study allow to conclude that ibrutinib significantly improves EFS, PFS and TTNT in patients with treatment-naïve early stage CLL when compared to placebo. There were no significant differences in adverse events between both study arms.
Shaji Kumar, Simon Harrison, Michele Cavo, Javier de la Rubia, et al.
Conclusion: Although the addition of Ven to Bd significantly improved PFS, ORR, ≥VGPR, and uMRD rates, the increased risk of death results in an unfavorable benefit-risk profile in a broad population. In t(11;14) pts, in addition to improvements in PFS, a positive trend in OS with Ven was observed, suggesting that a biomarker-driven approach with Ven may be most appropriate in MM.